Zonisamide for add-on treatment of refractory partial epilepsy: a European double-blind trial

摘要: The new antiepileptic drug zonisamide was evaluated in a European multicenter parallel-group double-blind trial as add-on treatment for 139 patients with refractory partial epilepsy. During complex seizures decreased by 27.7% compared to placebo (P < 0.05) and the median rate dropped from 12/month 7.1/month no changes group 0.007). 12-week phase 50% reduction of all recorded 29.9% treated vs. 9.4% during placebo. Complete remission observed 6.2%. plasma concentrations concomitant drugs did not change markedly when added. Adverse events, mostly fatigue, somnolence, dizziness ataxia, occurred 59.2% 27.9% Zonisamide withdrawn two due adverse events. Kidney stones were nor any relevant clinical chemistry or hematological changes. is an effective